Skip to main content
. 2023 Jan 2;13(2):595–608. doi: 10.1007/s13555-022-00876-x

Table 4.

Patients with treatment-emergent adverse events in period B

Adverse events, n (%) Placebo/Risankizumab 150 mg (n = 13) Placebo/Risankizumab 300 mg (n = 11) Risankizumab 150 mg (n = 61) Risankizumab 300 mg (n = 57)
Any TEAE 6 (46.2) 5 (45.5) 29 (47.5) 29 (50.9)
Most common AEsa
 Worsening of AD 2 (15.4) 1 (9.1) 7 (11.5) 5 (8.8)
 Nasopharyngitis 0 0 4 (6.6) 3 (5.3)
 Cellulitis 0 0 1 (1.6) 2 (3.5)
 Blood creatine phosphokinase increased 0 0 0 2 (3.5)
 C-reactive protein increased 0 0 2 (3.3) 0
 Pruritus 0 0 2 (3.3) 0
 Toothache 0 2 (18.2) 0 0
COVID-19-related TEAE 0 0 0 1 (1.8)
Serious AEsb 0 0 2 (3.3) 3 (5.3)
AEs leading to discontinuation 2 (15.4) 0 2 (3.3) 0
AEs leading to death 0 0 0 0
AEs of safety interest
 Opportunistic infections excluding tuberculosis and herpes zosterc 0 0 1 (1.6) 1 (1.8)
 Serious infections 0 0 1 (1.6) 1 (1.8)
 Malignant tumors 0 0 1 (1.6) 0
 Adjudicated anaphylactic reaction 0 0 0 0
 Malignant tumors excluding NMSC 0 0 0 0
 MACE 0 0 0 0
 Serious hypersensitivity 0 0 0 0
 Tuberculosis 0 0 0 0

AD atopic dermatitis, AEs adverse events, MACE major adverse cardiovascular event, NMSC non-melanoma skin cancer, TEAE treatment-emergent adverse event

aAEs reported in ≥ 2 patients in any treatment group

bIn the risankizumab 150 mg group, serious AEs included cardiac arrhythmia and cellulitis; the investigator believed there was a reasonable possibility that the cellulitis was treatment-related. In the risankizumab 300 mg group, serious AEs included worsening of osteoarthritis (n = 1); amaurosis fugax (n = 1); and coccyx fracture, vertebral fracture, and cellulitis in 1 patient; none of the serious AEs was considered to be treatment-related

cIncludes 1 patient each with cellulitis and 1 patient each with Kaposi’s varicelliform eruption in the continuous risankizumab 150 mg and 300 mg groups